02 Mar 2024
29 Feb 2024
People with epilepsy suffer from poor quality of life as a result of frequent seizure cognitive dysfunction, and a high risk of psychiatric co-morbidities. Beyond the role of vitamin D in bone health, it may be implicated in the functions of other systems of the body such as cardiovascular systems, cancer, autoimmune diseases, type 2 diabetes, and depression. The present study was conducted to study the effect of vitamin D administration on the quality of life in epileptic patients treated with antiepileptic drugs carbamazepine and levetiracetam. The study was performed with the participation of 67 patients newly diagnosed with epilepsy. They were taking the enzyme-inducing agent carbamazepine, and the non-enzyme-inducing agent levetiracetam. quality of life (QOLIE-31) of all patients was calculated by using the QOLIE-31 questionnaire (version 1.0). Patients then were divided into 2 groups according to the basis of the vitamin D level of the patients into group A, 33 patients, and group B, 34 patients. Group A received vitamin D supplements based on their vitamin D levels, while group B did not. The addition of vitamin D to group A showed an increase in the % of improvement rate as compared to group B which did not receive vitamin D supplementation. This improvement includes the patient awareness about his disease and how to deal with it, how used the drug, and its side effects. This work could provide evidence for the efficacy of vitamin D supplementation to patients with epilepsy through correction of the quality of life of the patients.